Cardinal Capital Management boosted its stake in shares of Sanofi (NYSE:SNY) by 4.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,196 shares of the company’s stock after buying an additional 1,769 shares during the period. Cardinal Capital Management’s holdings in Sanofi were worth $1,891,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the stock. Hamlin Capital Management LLC purchased a new stake in shares of Sanofi during the second quarter valued at approximately $56,725,000. American Century Companies Inc. increased its stake in shares of Sanofi by 306.8% in the second quarter. American Century Companies Inc. now owns 24,191 shares of the company’s stock valued at $1,012,000 after buying an additional 18,244 shares in the last quarter. Aviance Capital Management LLC increased its stake in shares of Sanofi by 113.7% in the second quarter. Aviance Capital Management LLC now owns 462,941 shares of the company’s stock valued at $19,374,000 after buying an additional 246,323 shares in the last quarter. HL Financial Services LLC purchased a new stake in shares of Sanofi during the second quarter valued at approximately $437,000. Finally, Rehmann Capital Advisory Group increased its stake in shares of Sanofi by 0.5% in the second quarter. Rehmann Capital Advisory Group now owns 5,571 shares of the company’s stock valued at $233,000 after buying an additional 26 shares in the last quarter. Institutional investors own 9.42% of the company’s stock.
Sanofi (NYSE:SNY) traded up 0.34% during trading on Monday, hitting $38.32. 1,356,425 shares of the stock were exchanged. The firm has a market capitalization of $98.64 billion, a price-to-earnings ratio of 21.25 and a beta of 0.98. Sanofi has a 1-year low of $37.41 and a 1-year high of $51.88. The company has a 50-day moving average price of $39.00 and a 200 day moving average price of $40.52.
Several brokerages have recently commented on SNY. Leerink Swann reiterated a “buy” rating on shares of Sanofi in a report on Monday, September 26th. Piper Jaffray Cos. assumed coverage on shares of Sanofi in a report on Friday, September 23rd. They set a “neutral” rating for the company. JPMorgan Chase & Co. restated an “underweight” rating on shares of Sanofi in a report on Thursday, September 15th. Jefferies Group restated a “hold” rating on shares of Sanofi in a report on Wednesday, September 14th. Finally, BNP Paribas upgraded shares of Sanofi from an “underperform” rating to a “neutral” rating in a report on Tuesday, September 13th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $60.50.
Sanofi, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.